ABSTRACT
A three-dose, randomized, double-blind parallel, placebo-controlled ocular tolerancy study was undertaken in 24 healthy, normal volunteers with two formulations of 2% MK-507 (L-671 152), a novel water-soluble, topical carbonic anhydrase inhibitor. In this study MK-507 was administered to humans for the first time. Subjects received 3 sequential drops of the test drug in one randomly selected eye (at 13:00, 14:00, and 14:10 o'clock): ten received 2% MK-507 formulated with 0.5% hydroxyethylcellulose (HEC); ten, 2% MK-507 with no HEC; two, vehicle with HEC; and two, vehicle without HEC. Local tolerance of 2% MK-507 was good with predominantly mild and transient local symptoms, somewhat fewer for the formulation without HEC. Significant lowering of intraocular pressure (IOP) by up to 7 mmHg was noted when comparing IOP 4 h and 5 h after the first dose with IOP 20 h and 19 h before the first dose in the treated eyes of subjects receiving MK-507. Slightly greater activity was noted when MK-507 was formulated with HEC.
Subject(s)
Antihypertensive Agents/toxicity , Carbonic Anhydrase Inhibitors/toxicity , Sulfonamides/toxicity , Thiophenes/toxicity , Adult , Cellulose/analogs & derivatives , Cellulose/toxicity , Double-Blind Method , Humans , Male , Ophthalmic SolutionsABSTRACT
MK-927 is a new topical carboanhydrase inhibitor with proven ability to lower intraocular pressure in glaucoma patients. Subjective and objective symptoms following topical application of MK-927 were evaluated in a randomized, double-blind, placebo-controlled study in which 24 healthy male volunteers took part. Symptoms were rated according to a visual analog scale by the volunteers and according to a grading scale by the examiner. The study showed good local tolerance of MK-927, comparable to that of Betaxolol.
Subject(s)
Betaxolol/pharmacology , Carbonic Anhydrase Inhibitors/pharmacology , Sulfonamides/pharmacology , Thiophenes/pharmacology , Administration, Topical , Betaxolol/administration & dosage , Carbonic Anhydrase Inhibitors/administration & dosage , Double-Blind Method , Drug Tolerance , Humans , Intraocular Pressure/drug effects , Male , Sulfonamides/administration & dosage , Thiophenes/administration & dosage , Time FactorsABSTRACT
The symptoms and clinical course of a case of birdshot chorioretinopathy are described. The patient was a 40-year-old woman. The condition can be treated with two types of medication, i.e., steroids and nonsteroidal anti-inflammatory drugs. Both appear to have a beneficial effect. Overall, however, the prognosis for this rare disease of unknown etiology remains uncertain. Given the slow progressive course, with spontaneous remissions and exacerbations, it is extremely difficult to evaluate the success of different forms of therapy.
Subject(s)
Chorioretinitis/drug therapy , Fluocortolone/administration & dosage , Administration, Oral , Chorioretinitis/diagnosis , Diclofenac/administration & dosage , Drug Administration Schedule , Fluorescein Angiography , Humans , Recurrence , Visual Acuity/drug effectsABSTRACT
The effects on intraocular pressure of the novel topical carbonic anhydrase inhibitor MK-927 were investigated for the first time in patients. Three drops of 2% MK-927 was administered in a two-center, double-masked, randomized, placebo-controlled, two-period crossover study in 25 patients with bilateral primary open angle glaucoma or ocular hypertension. At 4.5 hours after the dose, MK-927-treated eyes demonstrated a peak mean change of -7.7 mm Hg from a mean intraocular pressure of 27.8 mm Hg immediately before the dose; this compares with a change of -3.9 mm Hg from a mean intraocular pressure of 28.2 mm Hg when the same eyes were treated with placebo. The peak mean percent change in intraocular pressure in eyes treated with MK-927 was -26.7% at 6 hours after the dose compared with a change of -13.7% after treatment with placebo. No contralateral effect on intraocular pressure due to MK-927 was observed.
Subject(s)
Carbonic Anhydrase Inhibitors/therapeutic use , Glaucoma, Open-Angle/drug therapy , Ocular Hypertension/drug therapy , Sulfonamides/therapeutic use , Thiophenes/therapeutic use , Adult , Aged , Aged, 80 and over , Carbonic Anhydrase Inhibitors/administration & dosage , Clinical Trials as Topic , Double-Blind Method , Eye Color , Female , Humans , Intraocular Pressure/drug effects , Male , Middle Aged , Ophthalmic Solutions , Placebos , Random Allocation , Sulfonamides/administration & dosage , Thiophenes/administration & dosageABSTRACT
Cases of facial hemiatrophy manifest a variety of symptoms of monolateral atrophic processes of the skin, muscles, and bones. The symptoms are usually progressive and may also involve the ocular bulb and the orbit. In this paper the authors report the case of a 53-year-old woman with congenital fibrosis of all extraocular muscles and restricted motility of the enophthalmic bulb in all directions of gaze. Since, in addition, the ipsilateral side of the face is affected by discrete atrophy, this case has been classified as congenital, nonprogressive facial hemiatrophy. The findings are compared with those in other published cases.
